Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Cavlan explains that “they are brilliant at developing and bringing new drugs to market.”

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development Treatment DNA 105

The Premier Consulting Blog

JULY 9, 2023

Formally, both of these documents apply solely to marketing approval; informally, however, they are often used as general guidelines during clinical development to avoid obstacles that could result in extensive process changes, product reformulation, or safety qualification efforts. evaluating the safety of) impurities and degradants.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

The Premier Consulting Blog

MARCH 7, 2024

Depending on the gene therapy vector, microbial systems may be employed to produce vector DNA (such as in adeno associated virus (AAV)), in which case there may be bacterial cell banks and plasmid banks. A more rigorous identity test may sometimes be required, such as DNA sequencing of the entire AAV genome.

Production 52

Production Therapies DNA Virus 52

Drug Target Review

JUNE 6, 2023

Delivery of therapy is being evaluated through injections of DNA and RNA encoding IL-12, viral vectors, and other exploratory platforms designed to bring IL-12 in close proximity to the tumour and avoid excessive IL-12 in systemic circulation.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

APRIL 9, 2024

For his postdoctoral stay he joined the group of André Nussenzweig, where he started to work on DNA repair, particularly focusing on the role of histone H2AX. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.

RNA 64

RNA Cell Biology Clinical Development Disease 64

PerkinElmer

MAY 6, 2022

For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses. Researchers are therefore exploring the development of synthetic STING activators as potential cancer therapeutics.

Immune Response 52

Immune Response DNA Clinical Trials Clinical Development 52

Conversations in Drug Development Trends

JULY 8, 2024

With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation.

Clinical Trials 52

Clinical Trials Regulations Therapies Clinical Development 52

The Pharma Data

OCTOBER 19, 2020

Caris Precision Oncology Alliance members also have access to the Caris Pharmatech oncology trial network, which can help reduce the time it takes to identify and connect appropriate patients with novel targeted cancer therapies in clinical development.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

MAY 15, 2023

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

AUGUST 6, 2020

In addition, Inovio previously teamed up with Beijing Advaccine Biotechnology for work on its DNA vaccine candidate, INO-4800. China has several home-grown COVID-19 vaccines in clinical development. Outside of China, BioNTech and its partner Pfizer launched their 30,000-subject phase 3 efficacy trial last week.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 27, 2021

We are pleased to be advancing our second therapy into clinical development in our quest to bring transformative medicines to patients who need them,” said Bruce Goldsmith, Ph.D., We are excited to investigate the potential of PBFT02 as a treatment for FTD-GRN as we initiate our clinical development program in the coming months.”.

Therapies 52

Therapies Treatment Clinical Trials FDA 52

The Pharma Data

JANUARY 21, 2021

Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Drug Target Review

AUGUST 16, 2024

She has also served as a leader in clinical development and medical affairs at AbbVie, Kimberly-Clark and Johnson & Johnson. In those roles, she oversaw the direction, planning, execution and interpretation of clinical trial data.

Medical Schools 111

Medical Schools Nurses Research Production 111

The Pharma Data

JUNE 28, 2021

It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond. Compared to beta radiation, alpha radiation has a higher potency and shorter range.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

LifeSciVC

MARCH 1, 2023

They also highlighted why targeting the CD28 pathway overcomes some of these challenges and why CBL-B modulation, downstream of CD28 and other signaling receptors with clinical validation, may be more advantageous.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

DECEMBER 16, 2020

“Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. By the end of the first quarter of 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Alta Sciences

APRIL 17, 2024

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. Several small molecule GLP-1R agonists, such as oral orforglipron, are in late-stage clinical development. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In our experience, reaching a rapid drug substance material delivery to support toxicology studies is becoming a major milestone on the Phase I CMC clinical development path (Figure 1).

Drug Development 64

Drug Development Clinical Supply Production Protein Expression 64

The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Nvidia Developer: Drug Discovery

MARCH 21, 2023

New supercomputing-scale large language models (LLMs) that understand biology and chemistry text are helping scientists understand proteins, small molecules, DNA, and biomedical text. Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market.

Small Molecule 52

Small Molecule Drugs Clinical Trials DNA 52

The Pharma Data

APRIL 11, 2023

The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients. Forward-Looking Statements.

Therapies 40

Therapies Clinical Trials Production Treatment 40

Agency IQ

JULY 26, 2024

Postapproval manufacturing changes for biological products During clinical development or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling. Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

Agency IQ

APRIL 12, 2024

Additionally, six of these comments came from the same organization (Integrated DNA Technologies). Now the comments on the draft are in, and stakeholders had a lot to say The draft document was open for public comment for 90 days, during which time it received more than 160 comments.

Production 40

Production FDA Therapies Biochemical Assays 40

Covalent Modifiers

OCTOBER 25, 2023

To address this question, we have developed DrugMap, an atlas of cysteine ligandability compiled across 416 cancer cell lines. Leveraging these findings, we identify actionable cysteines in NFκB1 and SOX10 and develop corresponding covalent ligands that block the activity of these transcription factors.

DNA 162

DNA Clinical Development 162

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. In previous decades, isolation, sequencing and characterisation of DNA encoding a specific TCR was laborious and technically challenging. References Robinson R, McMurran C, McCully M, Cole D.

Engineering 110

Engineering DNA Virus Immune Response 110

Broad Institute

OCTOBER 11, 2023

Calico, together with AbbVie, has worked with TIDE to advance some of its drug discovery and development programs and now has projects — including the PTPN2 inhibitors — in various stages of preclinical and clinical development.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? DNA vectors in mouse models? What are Circio’s future plans for the circVec platform in terms of development and improvement to broaden its applications?

Therapies 59

Therapies RNA Protein Expression DNA 59

Creative Biolabs

MAY 25, 2022

These cytotoxic drugs include DNA base analogs, antimetabolic drugs, tubulin inhibitors, etc. Fu, 2022) Clinical research progress of ADC After decades of efforts, more than 100 ADCs are currently under clinical development. For decades, cytotoxic-based chemotherapy has been the main treatment for all kinds of cancers.

Therapies 52

Therapies Drugs DNA Treatment 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Immune Response Disease Clinical Trials 40

Codon

MARCH 20, 2023

Digital nanoreactors to control absolute stoichiometry and spatiotemporal behavior of DNA receptors within lipid bilayers. CRISPR-induced DNA reorganization for multiplexed nucleic acid detection. Combining fusion of cells with CRISPR-Cas9 editing for the cloning of large DNA fragments or complete bacterial genomes in yeast.

Virus 52

Virus RNA Engineering Small Molecule 52

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Pharma Data

FEBRUARY 22, 2022

He is co-founder and non-executive board member of the Hartwig Medical Foundation (large scale DNA analyses) and is a board member of the Center for Personalized Cancer Treatment and leads several innovative precision oncology clinical trials. He began his oncology development career at Rhône Poulenc Rorer Inc.

Clinical Trials 52

Clinical Trials DNA Science Clinical Development 52

Drug Target Review

DECEMBER 28, 2023

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. But DNA mutations can also result in changes to the proteins that are displayed on the surface of the cancer cell.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

APRIL 28, 2023

We strongly believe in the results of the PROpel trial, which demonstrated a clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.” In exploratory analyses of the BRCA m subgroup, patients in the LYNPARZA plus abi/pred arm had fewer rPFS (HR=0.23 [95% CI, 0.12-0.43])

FDA 40

FDA FDA Approval Trials Treatment 40